AI
Thursday, May 06, 2010 9:24:22 AM
Thanx Lang. Yes, it looks good.
Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX - News), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, presented results from its positive Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana.
UP in pre-market…Chart: trend should hold: Gann’s rule of 4. Watching vol.
Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX - News), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, presented results from its positive Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana.
UP in pre-market…Chart: trend should hold: Gann’s rule of 4. Watching vol.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
